Q2 EPS Forecast for ENDRA Life Sciences Lifted by Analyst

ENDRA Life Sciences Inc. (NASDAQ:NDRA) – Investment analysts at Ascendiant Capital Markets lifted their Q2 2026 earnings estimates for shares of ENDRA Life Sciences in a research note issued to investors on Sunday, May 31st. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will earn ($0.84) per share for the quarter, up from their prior forecast of ($1.14). Ascendiant Capital Markets currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for ENDRA Life Sciences’ current full-year earnings is ($4.65) per share. Ascendiant Capital Markets also issued estimates for ENDRA Life Sciences’ Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($4.11) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.76) EPS, Q3 2027 earnings at ($0.74) EPS, Q4 2027 earnings at ($0.74) EPS and FY2027 earnings at ($3.04) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $25.00.

ENDRA Life Sciences Stock Down 6.2%

NDRA opened at $4.73 on Thursday. ENDRA Life Sciences has a 12 month low of $2.96 and a 12 month high of $11.96. The company has a fifty day simple moving average of $5.09 and a 200 day simple moving average of $4.73. The stock has a market cap of $6.01 million, a P/E ratio of -0.58 and a beta of -0.04.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.14.

Hedge Funds Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new position in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent filing with the Securities and Exchange Commission. 1.19% of the stock is owned by institutional investors.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.